Musa Yilmaz

Hematology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 173 publications

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: April 22, 2026

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: April 12, 2026

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Journal: Cancer

Published: March 30, 2026

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission.

Journal: Haematologica

Published: March 23, 2026

Menin inhibition reshapes therapy in NPM1-mutated acute myeloid leukemia.

Menin inhibition reshapes therapy in NPM1-mutated acute myeloid leukemia.

Journal: Annals of translational medicine

Published: March 14, 2026

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 09, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

Modified Dhole-inspired optimization for maximum power extraction in photovoltaic systems under partial shading.

Modified Dhole-inspired optimization for maximum power extraction in photovoltaic systems under partial shading.

Journal: Scientific reports

Published: February 10, 2026

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Journal: American journal of hematology

Published: February 09, 2026

Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.

Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.

Journal: Blood advances

Published: January 23, 2026

Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.

Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.

Journal: Blood advances

Published: January 23, 2026

Showing 1-12 of 173

Last Updated: 09/26/2026